NCT00281320

Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)

A Randomized, Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects With Psychosis.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 122 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the safety and tolerability of Asenapine in elderly patients with psychosis.

Conditions

• Psychosis

Interventions

Type	Name	Description
DRUG	Asenapine	Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).

Timeline

• Start date: 2006-02-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2006-01-24
• Last updated: 2022-02-09
• Results posted: 2010-09-09